Functional role of tumor metastases suppressor gene, KAl1, in tumor progression

肿瘤转移抑制基因 KAl1 在肿瘤进展中的功能作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): More than 95% of cancer patients succumb to the disease due to metastases which is the hallmark of malignant cancer. Despite significant improvements in recent surgical techniques and chemotherapies, none of the current medical technologies "cure" the metastatic disease, and the patients who have acquired metastatic cancer inevitably die. Therefore, there is an urgent need for developing a novel target-specific therapy to metastatic tumor cells, which requires more comprehensive understanding of the molecular mechanism of metastases. The KAI1 gene (also called CD82), is a tumor metastases suppressor whose expression is significantly down-regulated in various types of cancers, and over-expression of this gene is capable of blocking metastases without affecting the primary tumor growth in vivo. However, the exact molecular mechanism of the metastases suppression has not been well understood. We have recently found that (i) KAI1 on tumor cells interacts with DARC on endothelial cell, (ii) the interaction of KAI1-DARC up-regulated p21 and down-regulated TBX2, (iii) this modulation of TBX2-p21 signal lead to senescence of tumor cell, and (iv) metastases suppressor activity of KAI1 is significantly compromised in DARC knockout mouse. These results highlight a previously unappreciated function of the DARC gene and identified the KAI-DARC signal as a novel candidate for potential therapeutic intervention for metastatic cancer. Based on our preliminary data we hypothesize that KAI1 forms a "multi-protein complex" with integrins, tetraspanins and PKC and that when the cancer cell intravasates, KAI1 binds to DARC on an endothelial cell followed by activation/inactivation of PKC, which results in up-regulation of p21 and induction of senescence of the cancer cell. To test this hypothesis, we will (i) examine the role of each factor of the multi-protein complex including integrins, kitenin, EGFR, c-Met, CD63, CD9 and PKC in the metastasis suppressor function of KAI1, (ii) examine the signal pathway of senescence induced by KAI1-DARC interaction and (iii) examine therapeutic potential of targeting KAI1-DARC signal by testing anti-KAI1 antibody and also by identifying small chemicals. Our long-term goal is to elucidate the functional role of KAI1 in tumor metastases suppression and to develop a novel therapeutic method which mimics the function of the KAI1 gene. We believe that the results of the proposed experiments should provide fundamental information to accomplish our ultimate goal, the control of tumor metastasis in cancer patients.
描述(申请人提供):超过95%的癌症患者死于转移,这是恶性肿瘤的标志。尽管最近的手术技术和化疗方法有了很大的进步,但目前的医学技术都没有“治愈”转移的疾病,获得转移癌症的患者不可避免地会死亡。因此,迫切需要开发一种针对转移瘤细胞的新的靶向特异性治疗方法,这就需要更全面地了解转移的分子机制。KAI1基因(又称CD82)是一种肿瘤转移抑制基因,在各种类型的肿瘤中表达显著下调,该基因的过表达能够在不影响体内原发肿瘤生长的情况下阻断转移。然而,抑制转移的确切分子机制还不是很清楚。我们最近发现(1)肿瘤细胞上的KAI1与内皮细胞上的DARC相互作用,(2)KAI1-DARC上调p21和下调TBX2的相互作用,(3)这种对TBX2-p21信号的调控导致肿瘤细胞衰老,(4)在DARC基因敲除小鼠中,KAI1的转移抑制活性显著降低。这些结果突出了DARC基因以前未被认识到的功能,并将KAI-DARC信号确定为潜在的转移性癌症治疗干预的新候选信号。根据我们的初步数据,我们假设KAI1与整合素、Tetraspanins和PKC形成一个“多蛋白复合体”,当癌细胞进入血管时,KAI1与内皮细胞上的DARC结合,随后PKC激活/失活,从而导致p21上调并诱导癌细胞衰老。为了验证这一假设,我们将(I)检测包括整合素、kitenin、EGFR、c-Met、CD63、CD9和PKC在内的多蛋白复合体中的每个因子在KAI1的转移抑制功能中的作用;(Ii)检测KAI1-DARC相互作用诱导衰老的信号通路;(Iii)通过检测抗KAI1抗体和识别小化学物质来检测靶向KAI1-DARC信号的治疗潜力。我们的长期目标是阐明KAI1在抑制肿瘤转移中的功能作用,并开发一种模拟KAI1基因功能的新的治疗方法。我们认为,拟议的实验结果应该为实现我们的最终目标--控制癌症患者的肿瘤转移--提供基本信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kounosuke Watabe其他文献

Kounosuke Watabe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kounosuke Watabe', 18)}}的其他基金

Role of inflammation and microRNA network in brain metastasis of breast cancer
炎症和microRNA网络在乳腺癌脑转移中的作用
  • 批准号:
    9036001
  • 财政年份:
    2016
  • 资助金额:
    $ 17.34万
  • 项目类别:
Roles of hyaluronic acid in cancer stem cell niche
透明质酸在癌症干细胞生态位中的作用
  • 批准号:
    8635035
  • 财政年份:
    2014
  • 资助金额:
    $ 17.34万
  • 项目类别:
Mechanism of tumor metastases suppression by Drg1
Drg1抑制肿瘤转移的机制
  • 批准号:
    8307675
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Mechanism of tumor metastases suppression by Drg1
Drg1抑制肿瘤转移的机制
  • 批准号:
    8569153
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Functional role of tumor metastases suppressor gene, KAl1, in tumor progression
肿瘤转移抑制基因 KAl1 在肿瘤进展中的功能作用
  • 批准号:
    8569176
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Functional role of tumor metastases suppressor gene, KAl1, in tumor progression
肿瘤转移抑制基因 KAl1 在肿瘤进展中的功能作用
  • 批准号:
    7934045
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Mechanism of tumor metastases suppression by Drg1
Drg1抑制肿瘤转移的机制
  • 批准号:
    7483667
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Functional role of tumor metastases suppressor gene, KAl1, in tumor progression
肿瘤转移抑制基因 KAl1 在肿瘤进展中的功能作用
  • 批准号:
    7663217
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Functional role of tumor metastases suppressor gene, KAl1, in tumor progression
肿瘤转移抑制基因 KAl1 在肿瘤进展中的功能作用
  • 批准号:
    8127915
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:
Mechanism of tumor metastases suppression by Drg1
Drg1抑制肿瘤转移的机制
  • 批准号:
    7934041
  • 财政年份:
    2007
  • 资助金额:
    $ 17.34万
  • 项目类别:

相似海外基金

Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
  • 批准号:
    10454419
  • 财政年份:
    2021
  • 资助金额:
    $ 17.34万
  • 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
  • 批准号:
    10672258
  • 财政年份:
    2021
  • 资助金额:
    $ 17.34万
  • 项目类别:
Novel Carbohydrate-binding Antibodies to Human Glycans Using the Lamprey System
使用 Lamprey 系统开发针对人类聚糖的新型碳水化合物结合抗体
  • 批准号:
    10293635
  • 财政年份:
    2021
  • 资助金额:
    $ 17.34万
  • 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
  • 批准号:
    2750554
  • 财政年份:
    2021
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Studentship
Covalent binding Antibodies as a Chemical Tool to Probe Immune Molecular Recognition
共价结合抗体作为探测免疫分子识别的化学工具
  • 批准号:
    565778-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Establishment of a novel serum diagnosis method for flaviviruses based on binding profiles of anti-flavivirus antibodies
基于抗黄病毒抗体结合谱建立黄病毒新型血清诊断方法
  • 批准号:
    20J22269
  • 财政年份:
    2020
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of Antigen Glycosylation in Mucin Binding by Monoclonal Antibodies
抗原糖基化在单克隆抗体粘蛋白结合中的作用
  • 批准号:
    10045898
  • 财政年份:
    2020
  • 资助金额:
    $ 17.34万
  • 项目类别:
Do anti-DNA antibodies play a role in the pathogenesis of systemic lupus erythematosus by binding/entering live cells?
抗 DNA 抗体是否通过结合/进入活细胞在系统性红斑狼疮的发病机制中发挥作用?
  • 批准号:
    16K08929
  • 财政年份:
    2016
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
N-Terminally fluorescent-labeled antibodies that show fluorescence change upon antigen-binding
N 末端荧光标记抗体,在抗原结合时显示荧光变化
  • 批准号:
    15K13739
  • 财政年份:
    2015
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
(i) Identification of single-molecule protein complexes involved in cellular transport of prosthetic groups (Moco and heme) (ii) Generation of monoclonal antibodies directed against protein motifs involved in binding prosthetic groups
(i) 鉴定参与假体基团(Moco 和血红素)细胞运输的单分子蛋白复合物 (ii) 生成针对参与结合假体基团的蛋白基序的单克隆抗体
  • 批准号:
    226653713
  • 财政年份:
    2012
  • 资助金额:
    $ 17.34万
  • 项目类别:
    Research Units
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了